Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
21–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is clinically stable, on current antipsychotic medication for at least 3 months and current dose for 2 months
Patient has a 6th grade reading level or better
Females are not pregnant, and those who can have children agree to remain abstinent or use acceptable birth control throughout the study
Patient has had a stable living arrangement for at least 3 months prior to study start
Patient is in general good health based on screening assessments
Patient has total Positive and Negative Syndrome Scale (PANSS) score between 36 and 75 at screening and at the first baseline visit
Patient has a Clinical Global Impressions - Severity (CGI-S) score less than or equal to 4 at screening and at the first baseline visit
You may not be if
Patient has a major disease/disorder that may interfere with cognitive testing (such as mental retardation) and/or pose a risk upon study participation
Patient has a history of head trauma with loss of consciousness greater than 15 minutes
Patient has had warfarin treatment, MAO inhibitors, clonazepam or clozapine within 1 month of screening
Patient has had ECT treatment within 6 months of screening
Patient requires treatment with antihistamines or certain other medications listed in the protocol
Patient has a history of liver disease that has been active within the last 2 years, or a history of cancer within the past 5 years
Patient has a history of alcohol or drug dependence within the past year or alcohol or drug abuse within 3 months of screening
Clareo Health | MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
